Position in TEVA
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$831,686
-$201,098 QoQ
Shares Held
24,548
-28.4% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#350
of 671 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 59%
Shared 0%
None 41%
Common Shares in TEVA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026EMERALD ADVISERS, LLC holds $22,866,585 across 5 Drug Manufacturers - Specialty & Generic names. TEVA ranks #2 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HIMS |
Hims & Hers Health, Inc.
|
608,509 | $21,097,007 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
This page
|
24,548 | $831,686 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,469 | $795,948 | |
| 4 | ANIP |
Ani Pharmaceuticals Inc
|
1,256 | $103,971 | |
| 5 | COLL |
Collegium Pharmaceutical, Inc
|
1,049 | $37,973 |
All Filings in TEVA
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $831,686 | 24,548 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $1,032,784 | 34,289 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $1,070,159 | 34,289 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $723,685 | 35,826 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $687,746 | 41,035 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $723,880 | 47,097 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $1,096,490 | 49,750 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $1,541,773 | 85,559 | Shares | Sole | 2024-10-29 | |
| 2024-06-30 | $1,409,638 | 86,747 | Shares | Sole | 2024-08-06 | |
| 2024-03-31 | $1,460,187 | 103,486 | Shares | Sole | 2024-05-08 | |
| 2023-12-31 | $691,274 | 66,214 | Shares | Sole | 2024-02-05 | |
| 2023-09-30 | $688,010 | 67,452 | Shares | Sole | 2023-10-26 | |
| No filing history on record for this holder in this stock. | ||||||